Navigation Links
Bioniche Responds to Australian Equine Influenza Outbreak
Date:9/6/2007

- Equimune(R) IV product a proven treatment -

BELLEVILLE, ON, Sept. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has increased its supply of Equimune(R)IV to Australia in order to be able to respond to anticipated increased demand as a result of that continent's equine influenza outbreak. The outbreak began in August, and according to one media report, a total of 3,376 horses on 405 properties are now suspected of having the virus.

"Bioniche wants to ensure that sufficient supply of Equimune IV is available to Australian veterinarians," said Jim Phillips, President of Bioniche Animal Health (global). "At the same time, we are ensuring that veterinarians have the information they require about our proprietary immunotherapy product and its efficacy in the treatment of equine influenza."

Equine influenza is a viral respiratory infection that causes flu like symptoms in horses and is from the group of viruses that causes flu in humans. Most horses exposed to the virus will show signs within a period of 1-5 days. Most viruses that are responsible for coughs and colds in horses result in mild symptoms, such as nasal discharge and coughing. Equine Influenza produces more severe symptoms, with horses developing a fever and a dry hacking cough. Horses become ill and are reluctant to eat or drink for several days, but usually recover in 2 to 3 weeks. The virus can be spread easily from horse to horse as a result of droplets and also from nasal discharge and from things like infected brushes and rugs. The disease is very contagious and there can be an almost 100% infection rate in a population that has been previously unexposed to the virus.

Australia and New Zealand are the only countries with significant equine industries that have been previously free from equine influenza. Horses in Australia are not vaccinated. Th
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Acute Gastroenteritis Responds To Treatment With Either Gatorade Or Pedialyte
2. Marijuana Abuse Responds to Psychotherapy, Overall Is Hard to Treat
3. Stubborn Ulcerative Colitis Responds to Arthritis Drug
4. Brain Responds Better to Name Brands
5. Australian Scientists Silence Cancer Gene
6. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
7. Australian Company Gets $10 million For Developing Skin Cancer Gel
8. World’s First Triple Transplant Performed by Australian Surgeon
9. Australian Surgeons Successfully Conduct Worlds First Triple Organ Transplant
10. Six Indians Win Australian Studies Fellowships
11. Australian Health funds stand accused
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5Health News:New approach to sickle-cell disease shows promise in mice 2Health News:Antidepressants May Change Your Personality 2Health News:Antidepressants May Change Your Personality 3Health News:Antidepressants May Change Your Personality 4Health News:The Dignity Memorial(R) Network Honors Four Individuals Who Gave the Gift of Life Through Organ and Tissue Donation 2Health News:The Dignity Memorial(R) Network Honors Four Individuals Who Gave the Gift of Life Through Organ and Tissue Donation 3Health News:Workforce Alliance Earns Grant to Train Health Care Workers 2Health News:Workforce Alliance Earns Grant to Train Health Care Workers 3
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3Hospital infections cost 241 billion in lost bed days 56007 1Hospital infections cost 241 billion in lost bed days 56007 2Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 1Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 2Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 3Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 4BioMarin to Present at the Baird Healthcare Conference 13799 1BioMarin to Present at the Baird Healthcare Conference 13799 2
Other Medicine Technology:Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress 2Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 2Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 4Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 5Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 6Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 8Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 9